MedTrace Logo

Quantification of Side Effects During Hepatitis C Therapy

NCT02545400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2015-10-05

No results posted yet for this study

Summary

This study aims to assess the frequency and severity of adverse events during Hepatitis C therapy with or without first generation protease inhibitors.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Vanessa Stadlbauer, MD · Medical University of Graz

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2015-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02545400 on ClinicalTrials.gov